Companie

Strides Pharma Science arm gets USFDA nod for HIV treatment drug

PTI New Delhi | Updated on January 15, 2021 Published on January 15, 2021

The approved product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Truvada tablets of Gilead Sciences

Drug firm Strides Pharma Science on Friday said its step-down wholly-owned subsidiary, Strides Pharma Global, has received approval from the US health regulator for Emtricitabine and Tenofovir Disoproxil Fumarate tablets, used to treat HIV.

The approved product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Truvada tablets of Gilead Sciences.

Strides Pharma Global, Singapore, has received approval for Emtricitabine and Tenofovir Disoproxil Fumarate tablets in the strengths of 200 mg/300 mg from the United States Food and Drug Administration (USFDA), Strides Pharma Science said in a regulatory filing.

Quoting IQVIA moving annual total (MAT) November 2020 data, Strides Pharma Science said the US market for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 200 mg/300 mg is approximately $2.4 billion.

“The product will be manufactured at the company’s facility at Bengaluru and will be marketed by Strides Pharma in the US market,” the company added.

The company has 127 cumulative abbreviated new drug application (ANDA) filings with USFDA of which 95 ANDAs have been approved and 32 are pending approval.

Shares of Strides Pharma Science were trading 0.83 per cent higher at ₹929 apiece on BSE.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on January 15, 2021
medicine
Strides Pharma Science Ltd
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.